New Tool IDs Mortality Risk After Bladder Cancer Surgery

This article originally appeared here.
Share this content:
New Tool IDs Mortality Risk After Bladder Cancer Surgery
New Tool IDs Mortality Risk After Bladder Cancer Surgery

WEDNESDAY, Oct. 11, 2017 (HealthDay News) -- A new risk-stratification tool is able to estimate mortality in patients with urothelial carcinoma of the bladder (UCB) after cystectomy, according to a study published online Sept. 7 in Cancer.

Christopher J. Welty, M.D., from the University of California, San Francisco, and colleagues identified 14,828 patients who underwent cystectomy with lymph node dissection for UCB from the Surveillance, Epidemiology, and End Results database (1988 to 2011), who were randomly divided into discovery and validation cohorts. The Cancer of Bladder Risk Assessment (COBRA) tool was developed using a Cox model that included age, tumor stage, and lymph node density.

The researchers found that patients with muscle invasive (T2), lymph node-positive disease had a survival curve similar to that seen in patients with extravesical (T3 and T4), lymph node-negative disease. There was a 1.61-fold increase in the risk of bladder cancer death in the development cohort with each point increase in the COBRA score (range, 0 to 7). The model was able to accurately stratify patients across risk levels in the development cohort and the two validation cohorts.

"The COBRA score offers a straightforward, validated risk-stratification tool that incorporates the relative contribution of tumor stage and lymph node involvement to patient prognosis after cystectomy for UCB," the authors write.

Several authors disclosed financial ties to the diagnostics industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Extended-Release Naltrexone Promising for Opioid Dependence

Extended-Release Naltrexone Promising for Opioid Dependence

Lower use of heroin, other illicit opioids with extended-release naltrexone in superiority analysis

New Expert Consensus Pathway for Mitral Regurgitation

New Expert Consensus Pathway for Mitral Regurgitation

Etiology, mechanism, severity, indications for treatment should be assessed after MR is identified

Many Dermatology Guideline Authors Get Industry Payments

Many Dermatology Guideline Authors Get Industry Payments

22 of 40 guideline authors receiving payments did not accurately disclose industry relationships

is free, fast, and customized just for you!

Already a member?

Sign In Now »